TERT promoter mutation as a diagnostic marker for diffuse gliomas

Affiliations

Comment

Koichi Ichimura. Neuro Oncol. 2019.

. 2019 Mar 18;21(4):417-418.

doi: 10.1093/neuonc/noz025.

¹ Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.

No abstract available

Comment on

Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
Diplas BH, Liu H, Yang R, Hansen LJ, Zachem AL, Zhao F, Bigner DD, McLendon RE, Jiao Y, He Y, Waitkus MS, Yan H. Diplas BH, et al. Neuro Oncol. 2019 Mar 18;21(4):440-450. doi: 10.1093/neuonc/noy167. Neuro Oncol. 2019. PMID: 30346624 Free PMC article.

1. Masutomi K, Hahn WC. Telomerase and tumorigenesis. Cancer Lett. 2003;194(2):163–172. - PubMed
1. Killela PJ, Reitman ZJ, Jiao Y, et al. . TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021–6026. - PMC - PubMed
1. Louis DN, Ohgaki H, Wiestler OD, et al. . WHO Classification of Tumours of the Central Nervous System. Revised 4th ed. Lyon, France: IARC; 2016.
1. Brat DJ, Aldape K, Colman H, et al. . cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol. 2018;136(5):805–810. - PMC - PubMed
1. Arita H, Yamasaki K, Matsushita Y, et al. . A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016;4(1):79. - PMC - PubMed